Using Pharmacogenomics (PGx) Results to Guide Post-operative Nausea and Vomiting (PONV) Treatment Practices: A Pilot Study
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Mayo Clinic
- 入组人数
- 92
- 试验地点
- 1
- 主要终点
- Episodes of Postoperative Vomiting
研究概览
简要总结
The Researchers overall goal is to evaluate the benefit and utility of preemptive genotypic data to guide post-operative nausea and vomiting treatment in the bariatric surgical population. The hypothesis is that using genotypic variation in CYP2D6 to select the appropriate 5HT3 serotonin receptor antagonist to treat PONV will decrease rates of PONV in the bariatric surgical population.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
CYP2D6 rapid metabolizer
Participants with CYP2D6 rapid metabolizer status will received granisetron for for post operative nausea and vomiting prophylaxis and treatment
干预措施: Granisetron (Drug)
CYP2D6 normal metabolizer
Participants with CYP2D6 poor or normal metabolizer status will received 4mg ondansetron for post operative nausea and vomiting prophylaxis and treatment
干预措施: Ondansetron (Drug)
结局指标
主要结局
Episodes of Postoperative Vomiting
时间窗: 0-48 hours post bariatric surgery
The total number count of post operative vomiting episodes were determined by nursing documentation or by treatment with rescue antinausea medication.
Episodes of Postoperative Nausea
时间窗: 0-48 hours post bariatric surgery
The total number count of post operative nausea episodes were determined by nursing documentation or by treatment with rescue antinausea medication.
次要结局
未报告次要终点
研究者
Yvette N. Martin, MD-PhD
Principal Investigator
Mayo Clinic